SG11201407579QA - Interleukin-2 fusion proteins and uses thereof - Google Patents
Interleukin-2 fusion proteins and uses thereofInfo
- Publication number
- SG11201407579QA SG11201407579QA SG11201407579QA SG11201407579QA SG11201407579QA SG 11201407579Q A SG11201407579Q A SG 11201407579QA SG 11201407579Q A SG11201407579Q A SG 11201407579QA SG 11201407579Q A SG11201407579Q A SG 11201407579QA SG 11201407579Q A SG11201407579Q A SG 11201407579QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- fusion proteins
- interleukin
- cambridge
- english
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 February 2014 (13.02.2014) WIPOIPCT (10) International Publication Number WO 2014/023752 A1 (51) International Patent Classification: A61K 47/48 (2006.01) C07K14/55 (2006.01) A61K 51/10 (2006.01) C12N15/62 (2006.01) A61K38/20 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/066516 7 August 2013 (07.08.2013) English (30) Priority Data: 61/681,676 10 August 2012 (10.08.2012) English US (71) Applicant: ROCHE GLYCART AG [CH/CH]; Wagis- trasse 18, CH-8952 Schlieren (CH). (72) Inventors: HOSSE, Ralf; Schmiedstrasse 8, CH-6330 Cham (CH). KLEIN, Christian; Chruezacherweg 41, CH- 8906 Bonstetten (CH). MOESSNER, Ekkehard; Felsen- burgweg 5, CH-8280 Kreuzlingen (CH). PETERSON, Laurence Bernard; 33 Hobart Road, Cambridge CB1 3PU (GB). UMANA, Pablo; Felsenrainstrasse 28, CH-8832 Wollerau (CH). WICKER, Linda; 5 Mulgrave Court, Cambridge CB1 7DP (GB). (74) Agent: KUENG, Peter; Grenzacherstrasse 124, CH-4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) CJ i> m CJ o o CJ (54) Title: INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF (57) Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates polynucleotides encoding such to fusion proteins, and vectors and host cells comprising such polynuc - leotides. The invention further relates to methods for producing the fusion proteins of the invention, and methods to of using them in the treatment of disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681676P | 2012-08-10 | 2012-08-10 | |
| PCT/EP2013/066516 WO2014023752A1 (en) | 2012-08-10 | 2013-08-07 | Interleukin-2 fusion proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407579QA true SG11201407579QA (en) | 2014-12-30 |
Family
ID=48948417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407579QA SG11201407579QA (en) | 2012-08-10 | 2013-08-07 | Interleukin-2 fusion proteins and uses thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20140044675A1 (en) |
| EP (1) | EP2882458B1 (en) |
| JP (1) | JP6526561B2 (en) |
| KR (1) | KR20150041628A (en) |
| CN (2) | CN104507504A (en) |
| AR (1) | AR092089A1 (en) |
| AU (1) | AU2013301562B2 (en) |
| BR (1) | BR112015002765A2 (en) |
| CA (1) | CA2873291A1 (en) |
| CL (1) | CL2014003322A1 (en) |
| CO (1) | CO7121348A2 (en) |
| CR (1) | CR20140532A (en) |
| EA (1) | EA201500206A1 (en) |
| HK (1) | HK1208827A1 (en) |
| IL (1) | IL236933A0 (en) |
| MA (1) | MA37894B1 (en) |
| MX (1) | MX2015001749A (en) |
| PE (1) | PE20150752A1 (en) |
| PH (1) | PH12014502767A1 (en) |
| SG (1) | SG11201407579QA (en) |
| TW (1) | TW201420607A (en) |
| WO (1) | WO2014023752A1 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20140303A1 (en) | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | MUTANT INTERLEUQUIN-2 POLYPEPTIDES |
| EA201892619A1 (en) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| CN109324190A (en) | 2012-12-11 | 2019-02-12 | 艾伯特叶史瓦大学爱因斯坦医学院 | High-throughput receptor: ligand identification method |
| MX370283B (en) | 2014-02-06 | 2019-12-09 | Hoffmann La Roche | Interleukin-2 fusion proteins and uses thereof. |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| MA40721A (en) * | 2014-08-06 | 2017-06-13 | The Univ Of Miami | INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE |
| HUE043038T2 (en) * | 2014-08-11 | 2019-07-29 | Delinia Inc | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| ES2841799T3 (en) * | 2015-08-06 | 2021-07-09 | Agency Science Tech & Res | Antibodies to IL2R-Beta / common gamma chain |
| CA3006477A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| JP2019522466A (en) | 2016-05-18 | 2019-08-15 | アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド | Mutant PD-L1 polypeptide, T cell regulatory multimeric polypeptide, and methods of use thereof |
| CA3019005A1 (en) | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| EA201991142A1 (en) | 2016-11-08 | 2019-10-31 | OPTIONS IL-2 FOR TREATMENT OF AUTOIMMUNE DISEASES | |
| CA3043630A1 (en) | 2016-12-22 | 2018-06-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN111010875B (en) | 2017-03-15 | 2024-04-05 | 库尔生物制药有限公司 | Methods for modulating immune responses |
| CN108623693B (en) * | 2017-03-20 | 2022-03-25 | 徐寒梅 | Fusion protein, preparation method thereof and application thereof in preparing medicaments for treating ophthalmic diseases, anti-inflammatory and antitumor |
| JOP20190271A1 (en) | 2017-05-24 | 2019-11-21 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use for immune related disorders |
| WO2019125732A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
| EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CN112105632A (en) * | 2018-01-24 | 2020-12-18 | 北京智康博药肿瘤医学研究有限公司 | Cytokine fusion proteins |
| EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| EA202092316A1 (en) | 2018-03-28 | 2021-05-25 | Бристол-Маерс Сквибб Компани | FUSION PROTEINS OF INTERLEUKIN-2 / ALPHA-RECEPTOR OF INTERLEUKIN-2 AND METHODS OF APPLICATION |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| WO2020127277A1 (en) | 2018-12-18 | 2020-06-25 | Robert Koch-Institut | A peptide-loaded mhc-i presenting cell and an il-2 with extended half-life for amplifying a cellular cytotoxic immune response |
| JP2023516774A (en) | 2020-03-06 | 2023-04-20 | サントル、オスピタリエ、ユニヴェルシテール、ド、ニーム | Low-Dose Human Interleukin-2 for Treatment of Amyotrophic Lateral Sclerosis |
| JP2023526723A (en) | 2020-05-12 | 2023-06-23 | キュー バイオファーマ， インコーポレイテッド | Multimeric T cell regulatory polypeptides and methods of use thereof |
| JP2023526282A (en) | 2020-05-13 | 2023-06-21 | ボナム セラピューティクス，インク． | Compositions of protein complexes and methods of use thereof |
| CN113912734A (en) * | 2020-07-08 | 2022-01-11 | 南京师范大学 | Fusion polypeptides and uses thereof |
| TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
| CN112724259B (en) * | 2020-11-16 | 2022-12-20 | 天津林达生物科技有限公司 | Fusion protein of human serum albumin and interleukin 2 and application thereof |
| CN116284380A (en) * | 2021-05-14 | 2023-06-23 | 厦门柏慈生物科技有限公司 | Interleukin 2 binding molecules, derivatives thereof, kits, methods of production and uses thereof |
| WO2024008126A1 (en) * | 2022-07-06 | 2024-01-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Il2 muteins and uses thereof |
| WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2388385B1 (en) | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | ORNAMENT FIXED BY PERMANENT MAGNETS |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| JPS60502136A (en) * | 1983-08-10 | 1985-12-12 | アムジエン インコーポレイテツド | Expression of interlukin 2 by microorganisms |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| ES2206447T3 (en) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | HUMANIZED ANTIBODY FOR HEREGULINE. |
| ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| ATE531812T1 (en) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | HUMANIZATION OF RODENT ANTIBODIES |
| JP2002505086A (en) * | 1998-02-25 | 2002-02-19 | レキシジェン ファーマシューティカルズ コーポレイション | Enhanced circulating half-life of antibody-based fusion proteins |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| DZ2788A1 (en) | 1998-05-15 | 2003-12-01 | Bayer Ag | Selective IL-2 agonists and antagonists. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
| US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2381025T3 (en) | 2001-12-04 | 2012-05-22 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| JP2007527242A (en) | 2004-03-05 | 2007-09-27 | カイロン コーポレーション | In vitro test system for predicting patient tolerance of therapeutic agents |
| MXPA06011199A (en) | 2004-03-31 | 2007-04-16 | Genentech Inc | Humanized anti-tgf-beta antibodies. |
| CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US20060110398A1 (en) | 2004-11-24 | 2006-05-25 | Schering Corporation | DAP-10 and uses thereof |
| JP2009542592A (en) * | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Compositions and methods for enhancing the effectiveness of an IL-2-mediated immune response |
| JP2010534469A (en) | 2007-07-25 | 2010-11-11 | アストラゼネカ アクチボラグ | KDR-directed targeted binding substances and uses thereof |
| US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| CN101970730A (en) | 2007-12-19 | 2011-02-09 | 森托科尔奥索生物科技公司 | Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods |
| DE102008023820A1 (en) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells |
| JP5766124B2 (en) | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | Compositions and methods for the treatment of inflammatory and autoimmune diseases |
| SG187746A1 (en) | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| CU23923B1 (en) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY |
| PE20140303A1 (en) | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | MUTANT INTERLEUQUIN-2 POLYPEPTIDES |
| CN103732241A (en) | 2011-03-11 | 2014-04-16 | 公共事业救济局-巴黎医院 | Use of low dose Il-2 for treating autoimmune - related or inflammatory disorders |
| PT2691417T (en) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Antibody fc variants |
| EA201892619A1 (en) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
| EP3626739A1 (en) | 2011-06-24 | 2020-03-25 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| MX370283B (en) | 2014-02-06 | 2019-12-09 | Hoffmann La Roche | Interleukin-2 fusion proteins and uses thereof. |
| MA40721A (en) | 2014-08-06 | 2017-06-13 | The Univ Of Miami | INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE |
-
2013
- 2013-08-06 US US13/960,149 patent/US20140044675A1/en not_active Abandoned
- 2013-08-07 CN CN201380041053.1A patent/CN104507504A/en active Pending
- 2013-08-07 EA EA201500206A patent/EA201500206A1/en unknown
- 2013-08-07 SG SG11201407579QA patent/SG11201407579QA/en unknown
- 2013-08-07 CN CN202010331382.1A patent/CN111635460A/en active Pending
- 2013-08-07 WO PCT/EP2013/066516 patent/WO2014023752A1/en active Application Filing
- 2013-08-07 JP JP2015525869A patent/JP6526561B2/en not_active Expired - Fee Related
- 2013-08-07 KR KR20157003397A patent/KR20150041628A/en not_active Application Discontinuation
- 2013-08-07 MX MX2015001749A patent/MX2015001749A/en unknown
- 2013-08-07 AU AU2013301562A patent/AU2013301562B2/en not_active Ceased
- 2013-08-07 PE PE2014002251A patent/PE20150752A1/en not_active Application Discontinuation
- 2013-08-07 CA CA2873291A patent/CA2873291A1/en not_active Abandoned
- 2013-08-07 BR BR112015002765A patent/BR112015002765A2/en active Search and Examination
- 2013-08-07 EP EP13745844.4A patent/EP2882458B1/en active Active
- 2013-08-07 MA MA37894A patent/MA37894B1/en unknown
- 2013-08-09 TW TW102128732A patent/TW201420607A/en unknown
- 2013-08-09 AR ARP130102839A patent/AR092089A1/en unknown
-
2014
- 2014-10-31 CO CO14241630A patent/CO7121348A2/en unknown
- 2014-11-20 CR CR20140532A patent/CR20140532A/en unknown
- 2014-12-04 CL CL2014003322A patent/CL2014003322A1/en unknown
- 2014-12-10 PH PH12014502767A patent/PH12014502767A1/en unknown
-
2015
- 2015-01-26 IL IL236933A patent/IL236933A0/en unknown
- 2015-10-02 HK HK15109669.4A patent/HK1208827A1/en unknown
- 2015-12-11 US US14/967,019 patent/US20160090407A1/en not_active Abandoned
-
2017
- 2017-09-05 US US15/695,899 patent/US10562949B2/en not_active Expired - Fee Related
-
2020
- 2020-02-05 US US16/783,141 patent/US11365232B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1208827A1 (en) | 2016-03-18 |
| CN104507504A (en) | 2015-04-08 |
| PH12014502767A1 (en) | 2015-02-09 |
| CR20140532A (en) | 2015-01-12 |
| EP2882458B1 (en) | 2018-07-11 |
| KR20150041628A (en) | 2015-04-16 |
| JP6526561B2 (en) | 2019-06-05 |
| BR112015002765A2 (en) | 2018-03-13 |
| CO7121348A2 (en) | 2014-11-20 |
| CL2014003322A1 (en) | 2015-02-13 |
| JP2015530984A (en) | 2015-10-29 |
| MX2015001749A (en) | 2015-06-05 |
| IL236933A0 (en) | 2015-03-31 |
| EA201500206A1 (en) | 2016-04-29 |
| EP2882458A1 (en) | 2015-06-17 |
| TW201420607A (en) | 2014-06-01 |
| AU2013301562A1 (en) | 2014-11-20 |
| US11365232B2 (en) | 2022-06-21 |
| US20200172591A1 (en) | 2020-06-04 |
| CN111635460A (en) | 2020-09-08 |
| AR092089A1 (en) | 2015-03-25 |
| CA2873291A1 (en) | 2014-02-13 |
| US10562949B2 (en) | 2020-02-18 |
| US20160090407A1 (en) | 2016-03-31 |
| MA37894A1 (en) | 2018-07-31 |
| MA37894B1 (en) | 2020-01-31 |
| PE20150752A1 (en) | 2015-05-15 |
| US20180009868A1 (en) | 2018-01-11 |
| WO2014023752A1 (en) | 2014-02-13 |
| AU2013301562B2 (en) | 2017-04-06 |
| US20140044675A1 (en) | 2014-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408746XA (en) | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201408224SA (en) | Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same |